Business Context and Reporting Period
This Form 8-K filing by Maze Therapeutics, Inc. (MAZE) reports a corporate governance event dated September 2, 2025. The filing details the appointment of a new Chief Financial Officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $500,000 per year.
- Discretionary Bonus: Up to 40% of base salary.
- Sign-on Bonus: $50,000 (subject to clawback if service is less than one year).
- Equity Grant: Option to purchase 325,000 shares of common stock.
Material Changes
The primary material change is the appointment of Misbah Tahir as Chief Financial Officer and principal financial officer, effective September 2, 2025. Mr. Tahir previously served as CFO of IGM Biosciences, Inc. (2019–2025) and held finance leadership roles at Dermira, Inc., Onyx Pharmaceuticals, Inc., and Human Genome Sciences Inc.
Outlook, Risks, and Contingencies
The filing outlines specific severance and change-in-control contingencies for the new CFO:
- Termination Without Cause (Outside Change in Control): Entitles the executive to nine months of base salary and nine months of medical benefits.
- Termination Without Cause or Good Reason (Near Change in Control): Entitles the executive to one year of base salary, the target bonus, and COBRA premium payments for up to 12 months. Additionally, outstanding equity awards (excluding performance-based ones) would fully vest.
The full Offer Letter is to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Investor Verification Checklist
- Verify the vesting schedule details for the 325,000 share option grant (25% at one year, then monthly).
- Review the full Offer Letter in the upcoming Form 10-Q for complete terms and conditions.
- Assess the impact of the new CFO's background on the company's financial strategy and capital raising efforts.
- Confirm the company's current cash position to ensure it can support the new executive compensation package and potential severance liabilities.